Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Relatlimab vs Nivolumab in resected melanoma
NCT05002569Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2021
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 25
01
Overview
A Phase 3 trial of relatlimab in melanoma, sponsored by Bristol Myers Squibb. Started Oct 2021; status: terminated.
02
Drugs
relatlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05002569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05002569.